<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00831636</url>
  </required_header>
  <id_info>
    <org_study_id>CP4055-204</org_study_id>
    <nct_id>NCT00831636</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer</brief_title>
  <official_title>A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clavis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clavis Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is non randomised, open label, dose finding, efficacy and safety study, enrolling
      patients with advanced (stage III and IV) ovarian cancer It will be conducted in two
      successive phases. Phase II has a two-step design
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I

        -  Three eligible patients will be enrolled at each dose level (DL), according to standard
           dose escalation decision rules

        -  Patients will receive CP-4055 at increasing DLs until the maximum tolerated dose and the
           recommended dose (RD) have been established

      Phase II

        -  Step 1 (The patient inclusion may stop after this step):

             -  Patients will be enrolled at the RD until there are maximum 16 evaluable patients
                at this DL

        -  Step 2:

             -  Depending on the response rate at step 1, up to 26 patients will be included and
                treated at step 2
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Determine recommended dose for phase II studies of CP-4055 when given five consecutive days twice in a 4 week schedule, D1-5 and D8(+2)-12(+2) q4w</measure>
    <time_frame>August 2009/June 2010</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Determine the antitumour activity of CP-4055</measure>
    <time_frame>August 2009/June 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine pharmacokinetic (PK) parameters</measure>
    <time_frame>August 2009/June 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore the time to progression (TTP)</measure>
    <time_frame>August 2009/June 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigate the duration of tumour response</measure>
    <time_frame>August 2009/June 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the nature and degree of toxicity of CP-4055 in this patient population</measure>
    <time_frame>August 2009/June 2010</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Open label CP-4055</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: Dose escalation Phase II: Fixed dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-4055</intervention_name>
    <description>D1-5 and D8(+2)-12(+2) q4w</description>
    <arm_group_label>Open label CP-4055</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-4055</intervention_name>
    <description>IV administration day 1-5 and day 8-12 in a 4 week schedule</description>
    <arm_group_label>Open label CP-4055</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically documented advanced epithelial ovarian cancer
             measurable with CT and/or MRI

          -  Received prior chemotherapy regimen(s) for ovarian cancer, at least one being a
             platinum based therapy (PBT)

          -  Evidence of platinum resistant or refractory disease

          -  ECOG Performance Status 0 - 1

          -  Life expectancy &gt; 3 months

          -  Signed informed consent (IC)

          -  Women of child-bearing potential must have a negative serum or urine pregnancy test.
             Nursing patients are excluded.

          -  Women of child-bearing potential must not become pregnant while participating in the
             study

          -  Adequate haematological and biological functions

        Exclusion Criteria:

          -  Patients with mixed mullerian tumours (MMT) (carcinosarcomas)

          -  Known brain metastases

          -  Another known active cancer within the last 5 years

          -  Radiotherapy to more than 30 % of bone marrow

          -  Participation in another therapeutic clinical study within 30 days of enrolment or
             during this clinical study

          -  Concomitant treatment with a non-permitted medication

          -  A history of allergic reactions or sensitivity attributed to compounds of similar or
             biological composition to CP-4055, i.e., ara-C and/or egg

          -  Any serious concomitant systemic disorders incompatible with the clinical study

          -  Any significant CNS or psychiatric disorder(s) that would hamper the patient's
             compliance

          -  Pregnancy or breastfeeding

          -  Known positive status for HIV and/or hepatitis B or C

          -  Drug and/or alcohol abuse

          -  Any reason why, in the investigator's opinion, the patient should not participate
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandro Pignata, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Oncology B, National Cancer Institute, Via Mariano Semmola, IT-80131 Naples, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg, Gynecologic Oncology, Herestraat 49</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology C, National Cancer Institute, Centro di Riferimento Oncologico</name>
      <address>
        <city>Aviano (PN)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology B, National Cancer Institute, Via Mariano Semmola</name>
      <address>
        <city>Naples</city>
        <zip>IT-80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Catholic University of the Sacred Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology, Fatebenefratelli Hospital, Isola Tiberina</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.clavispharma.com/</url>
    <description>Clavis Pharma Home Page</description>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2009</study_first_submitted>
  <study_first_submitted_qc>January 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2009</study_first_posted>
  <last_update_submitted>September 12, 2013</last_update_submitted>
  <last_update_submitted_qc>September 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CP-4055</keyword>
  <keyword>Cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Solid tumors</keyword>
  <keyword>advanced ovarian cancer</keyword>
  <keyword>stage III and IV ovarian cancer</keyword>
  <keyword>advanced epithelian ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

